Search in biosurfit Start writing...

- PT2020

SPEF



Designation of the project | R&D projects: SPEF - Surface Plasmon Resonance enhanced fluorescence
Project Code | LISBOA-01-0247-FEDER-011135
Main goal | Reinforce research, technology development and innovation
Region of activity | Lisbon 
Beneficiary | biosurfit S.A.


Approval date | 19-04-2016
Start date | 01-01-2016
Data de conclusão | 31-12-2017
Custo total elegível | 1 002 826,75€
EU Financing | 401 130,70€5€

Project summary
The present proposal aims at the development of an innovative high-performance Point of Care testing product, leveraging on biosurfit' s Intellectual Property and accumulated knowhow, to implement Surface Plasmon Resonance enhanced fluorescence (SPEF) detection in spinit® products. These activities will gain from established processes and infra-structure at biosurfit and will merge into a major integration validation activity using two clinically relevant panels in Cardiology and Endocrinology.

Strategic goals
  • Make the spinit® technology a global solution being one of the top players in the PoC diagnostic market; 
  • Attract intelligent and international strategic investment to maintain national production and generate investment; 
  • Create and develop an R&D and manufacture centre with a specialized team contributing to the country’s development and supporting the launch of new projects at the diagnostics market; 
  • Continuously invest in technological innovation with annual submission of at least 3 new international patents to solve existing technical problems, contributing to a reduction of costs and improvement of diagnostic performance;
  • Actively participate in the preposition of the companion diagnostics and assisted living with remote clinical monitoring, through the development and launch in the market of diagnostic solutions with high performance and reduced investment for the end users and their integration with the health systems;
        SPR




        Designation of the project | R&D projects: SPEF - Surface Plasmon Resonance enhanced fluorescence
        Project Code | ALT20-03-0247-FEDER-011135;
        Main goal | Reinforce research, technology development and innovation
        Region of activity | Alentejo
        Beneficiary | biosurfit S.A.

        Approval date | 19-04-2016
        Start date | 01-01-2016
        End Date | 31-12-2017
        Total eligible value | 492 311,30€
        EU Financing | 352 732,13€

        Project summary
        The present proposal aims at the development of an innovative high-performance Point of Care testing product, leveraging on biosurfit' s Intellectual Property and accumulated knowhow, to implement Surface Plasmon Resonance enhanced fluorescence (SPEF) detection in spinit® products. These activities will gain from established processes and infra-structure at biosurfit and will merge into a major integration validation activity using two clinically relevant panels in Cardiology and Endocrinology.

        Strategic goals
        • Make the spinit® technology a global solution being one of the top players in the PoC diagnostic market;
        • Attract intelligent and international strategic investment to maintain national production and generate investment;
        • Create and develop an R&D and manufacture centre with a specialized team contributing to the country’s development and supporting the launch of new projects at the diagnostics market;
        • Continuously invest in technological innovation with annual submission of at least 3 new international patents to solve existing technical problems, contributing to a reduction of costs and improvement of diagnostic performance;
        • Actively participate in the preposition of the companion diagnostics and assisted living with remote clinical monitoring, through the development and launch in the market of diagnostic solutions with high performance and reduced investment for the end users and their integration with the health systems;

        New Product Panels
        Failed to load the Page Fonts We apologize, but the user experience may not be the best! Got it